Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Agency
National Institutes of Health
Posted
Oct 14, 2026
Due Date
Oct 11, 2029
Description
<p>This Notice of Funding Opportunity (NOFO) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should focus on one or more of the following: i) identifying what environmental or lifestyle exposures are driving the increase in the incidence of non-hereditary EOCs, and how these factors vary by patient demographics; ii) examining the biological mechanisms and host responses that underlie the increase in EOCs; and iii) identifying how those at increased risk of developing EOCs can be identified more effectively.</p><p>In an effort to streamline the application process and sustain momentum in this critical research area, this NOFO supports both exploratory/developmental and standard research projects through a grant award instrument. </p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 361438
- Solicitation Number
- PAR-28-014
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health